What is the 13F Pro Quality Score for BCRX?

13F Pro ranks BIOCRYST PHARMACEUTICALS INC (BCRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BCRX's current score at https://13fpro.ai/company/BCRX (free sign-up required for the full ranking).

Which hedge funds own the most BCRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BCRX include BlackRock,, RA CAPITAL MANAGEMENT, L.P., STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/BCRX as soon as new 13F filings post.

Where does 13F Pro source BCRX data?

All BIOCRYST PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. BIOCRYST PHARMACEUTICALS INC files with the SEC under CIK 882796. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BCRX in?

BIOCRYST PHARMACEUTICALS INC (BCRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives BCRX's revenue?

Per BIOCRYST PHARMACEUTICALS INC's latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: ORLADEYO product sales and royalties ($306.5M, +15% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/BCRX.

What are BCRX's largest expenses?

BIOCRYST PHARMACEUTICALS INC's latest 10-Q reports these as the largest expense items: Acquired in-process research and development ($697.8M, N/A); Research and development ($112.3M, +39% YoY); Cost of product sales ($9.2M, +25% YoY). Sourced directly from SEC EDGAR filing text for Q2 2026 (six months ended June 30, 2026).

How often is BCRX research updated on 13F Pro?

BCRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIOCRYST PHARMACEUTICALS INC(BCRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 882796 BCRX stock profile & AI dashboard →

13F Pro Quality Score

53.2/100

Rank #1,402 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

94.9/100

Profitability

11.5/100

Balance Sheet

1.8/100

Earnings Quality

61.3/100

Free Cash Flow

90.6/100

Institutional Flow

79.5/100

Revenue Scale

48.9/100

Dilution Risk

16.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BCRX Scores 53/100

exact factor attribution · 2026-09-11

BCRX's composite is driven by revenue growth and free cash flow, held back by profitability and capital efficiency. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.0 pts

95th pct

Free cash flow

+6.1 pts

91th pct

Institutional flow

+1.5 pts

80th pct

Earnings quality

+1.1 pts

61th pct

Scale

-0.2 pts

49th pct

Shareholder dilution

-1.7 pts

17th pct

Earnings growth

-2.0 pts

10th pct

Capital efficiency

-4.8 pts

2th pct

Profitability

-5.8 pts

12th pct

Latest change (2026-08-05): 37 → 67 · ↑ Profit margin 7→82; ↑ Capital efficiency 0→95

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in BCRX

Events flagged as statistical outliers against BCRX's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-05
BCRX quality score jumped 30 points (37→67) on a new filing
View source filing →

BCRX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BIOCRYST PHARMACEUTICALS INC (BCRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BCRX at 53.2/100 on a 32-signal composite quality model, placing it at rank #1,402 of 2,961 stocks — the top half of the AI-ranked universe. BCRX scores in the top quartile across revenue growth (94.9), free cash flow (90.6), institutional flow (79.5). Areas of concern include balance sheet strength (1.8) and profitability (11.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIOCRYST PHARMACEUTICALS INC reports quarterly revenue of $218.3M, net income of $78.4M, free cash flow of $104.1M. Top institutional holders of BCRX by reported 13-F value include BlackRock, RA CAPITAL MANAGEMENT, L.P., STATE STREET, based on the most recent SEC filings. BCRX trades on the Nasdaq exchange and files with the SEC under CIK 882796. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOCRYST PHARMACEUTICALS INC directly from SEC EDGAR. BIOCRYST PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 53 and 73 since 2026, currently 53.2 — a declining long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about BIOCRYST PHARMACEUTICALS INC

Quirks, history, and lore behind BCRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in North Carolina.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, driven almost entirely by a single approved antiviral drug — a high-stakes bet on one molecule.
3
The History
Founded in the 1980s, the company spent decades as a clinical-stage also-ran before finally landing a commercial product — patience measured in generations of investors.
4
The Secret
Its specialty is rare and serious diseases, with a particular obsession with hereditary angioedema (HAE) — a condition so uncommon most doctors go a career without seeing a case.
5
The Lore
Its oral HAE therapy became the first pill approved to prevent HAE attacks, threatening to displace injectable rivals and setting off a patent-war frenzy in the rare-disease world.
6
The Giveaway
Ticker BCRX, maker of ORLADEYO (berotralstat) — the once-daily capsule that put a tiny Durham biotech on the map for HAE patients worldwide.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving BCRX's Business? Latest 10-Q Breakdown

AI-extracted from BIOCRYST PHARMACEUTICALS INC's 10-Q filed 2026-08-05 — Q2 2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

BioCryst reported H1 2026 revenues of $374.7M (+21% YoY), driven by ORLADEYO sales and $55.7M license revenue from Neopharmed navenibart deal, but recorded $643.4M net loss due to $697.8M non-cash IPR&D charge from Astria acquisition.

Biggest Revenue Drivers

ORLADEYO product sales and royalties$306.5M+15% YoY

Net price increase and increased volume from continued strong market dynamics; excludes European business sold Oct 2025.

Biggest Revenue Drivers

Total revenue: $374.7M+21% YoY

ORLADEYO product sales and royalties$306.5M+15% YoY

Net price increase and increased volume from continued strong market dynamics; excludes European business sold Oct 2025.

Largest Expense Items

Acquired in-process research and development$697.8MN/A

Non-cash charge for navenibart IPR&D asset acquired in Astria Therapeutics merger on January 23, 2026.

Research and development$112.3M+39% YoY

$27.1M navenibart Phase 3 development from acquisition; $14.2M increase in compensation from Astria merger costs including $10.7M stock option payout for post-combination service.

Cost of product sales$9.2M+25% YoY

Increase from higher ORLADEYO partner sales; decrease from European business divestiture.

Margins: Gross margin improved with ORLADEYO expansion and licensing revenue, but operating results severely impacted by $697.8M non-cash IPR&D charge related to Astria acquisition accounting as asset acquisition under ASC 805.

Watch Items from the Filing

Specialty pharmacy concentration: Single specialty pharmacy represented ~97% of ORLADEYO product sales in Q2 2026 and H1 2026 (~95%). On August 5, 2026, company transitioned to new sole-source specialty pharmacy, creating transition execution risk.
Navenibart clinical and commercial execution: Phase 3 ALPHA-ORBIT trial enrollment completed June 2026; Neopharmed European license received $70M upfront and eligible for $275M milestones. Success dependent on trial outcomes and manufacturing scale-up.
Patent litigation and generic competition: Annora ANDA challenges to four ORLADEYO patents expiring May 2040 (two Orange Book patents expire 2035); litigation filed March 2025, in early stages with outcome and materiality uncertain.
Birmingham Closure Plan: Announced June 2026 to discontinue internal discovery and close Birmingham facility; estimated $7.2M one-time costs for severance; majority of employee terminations in 2026, some in Q1 2027. Shifts strategy to external innovation.
$400M Blackstone term loan due January 2031 secured by substantially all assets; minimum liquidity covenant applies. Interest-only payments at SOFR floor 1.75% + 4.50% = 8.50% effective Q2 2026; PIK election available for 200 bps through Jan 2028.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$218.3M

Net Income

Q2 2026

$78.4M

Free Cash Flow

Q2 2026

$104.1M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+94.1% YoY

$874.8MFY 2025

FY22 $270.8MFY23 $331.4MFY24 $450.7MFY25 $874.8M

Net Income

+396.9% YoY

$263.9MFY 2025

FY22 $-247.1MFY23 $-226.5MFY24 $-88.9MFY25 $263.9M

Operating Income

+13508.9% YoY

$341.0MFY 2025

FY22 $-148.4MFY23 $-103.7MFY24 $-2.5MFY25 $341.0M

EPS (Diluted)

+381.4% YoY

$1.21FY 2025

FY22 $-1.33FY23 $-1.18FY24 $-0.43FY25 $1.21

Total Assets

+4.8% YoY

$514.2MFY 2025

FY22 $550.0MFY23 $517.0MFY24 $490.4MFY25 $514.2M

Total Debt

-100.0% YoY

$0.00FY 2025

FY22 $231.6MFY23 $303.2MFY24 $314.9MFY25 $0.00

Op. Cash Flow

+767.8% YoY

$347.4MFY 2025

FY22 $-161.8MFY23 $-95.1MFY24 $-52.0MFY25 $347.4M

Free Cash Flow

+749.0% YoY

$344.9MFY 2025

FY22 $-163.2MFY23 $-97.3MFY24 $-53.1MFY25 $344.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$874.8M +94.1%	$450.7M +36.0%	$331.4M +22.4%	$270.8M +72.3%	$157.2M +782.4%	$17.8M
Net Income	$263.9M +396.9%	$-88.9M +60.8%	$-226.5M +8.3%	$-247.1M -34.3%	$-184.1M -0.7%	$-182.8M
Operating Income	$341.0M +13508.9%	$-2.5M +97.5%	$-103.7M +30.1%	$-148.4M +16.5%	$-177.7M -1.7%	$-174.8M
EPS (Diluted)	$1.21 +381.4%	$-0.43 +63.6%	$-1.18 +11.3%	$-1.33 -29.1%	$-1.03 +5.5%	$-1.09
Total Assets	$514.2M +4.8%	$490.4M -5.1%	$517.0M -6.0%	$550.0M -6.5%	$588.2M +75.7%	$334.7M
Total Debt	$0.00 -100.0%	$314.9M +3.8%	$303.2M +30.9%	$231.6M -22.3%	$298.1M +143.2%	$122.6M
Operating Cash Flow	$347.4M +767.8%	$-52.0M +45.3%	$-95.1M +41.2%	$-161.8M -13.9%	$-142.2M -5.2%	$-135.1M
Free Cash Flow	$344.9M +749.0%	$-53.1M +45.4%	$-97.3M +40.4%	$-163.2M -12.9%	$-144.5M -6.6%	$-135.6M

Get alerted when BCRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIOCRYST PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BCRX

BlackRock, Inc.
$238.9M23,893,036 sh
RA CAPITAL MANAGEMENT, L.P.
$158.3M15,827,186 sh
STATE STREET CORP
$151.9M15,191,098 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$151.0M15,096,403 sh
VANGUARD CAPITAL MANAGEMENT LLC
$113.6M11,364,236 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$111.4M11,139,158 sh
TCG Crossover Management, LLC
$110.2M11,020,968 sh
PERCEPTIVE ADVISORS LLC
$103.1M10,308,888 sh
Jupiter Topco LLC
$95.3M9,540,764 sh
Vestal Point Capital, LP
$83.0M8,300,000 sh

Fund	Value	Shares
BlackRock, Inc.	$238.9M	23,893,036
RA CAPITAL MANAGEMENT, L.P.	$158.3M	15,827,186
STATE STREET CORP	$151.9M	15,191,098
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$151.0M	15,096,403
VANGUARD CAPITAL MANAGEMENT LLC	$113.6M	11,364,236
VANGUARD PORTFOLIO MANAGEMENT LLC	$111.4M	11,139,158
TCG Crossover Management, LLC	$110.2M	11,020,968
PERCEPTIVE ADVISORS LLC	$103.1M	10,308,888
Jupiter Topco LLC	$95.3M	9,540,764
Vestal Point Capital, LP	$83.0M	8,300,000

Companies Similar to BCRX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

TARS

Tarsus Pharmaceuticals, Inc.

AI score

Very similar · 20 shared holders

Vestal Point Capital, LP Frazier Life Sciences Management, L.P.Parkman Healthcare Partners LLC

TVTX

Travere Therapeutics, Inc.

AI score

Similar quality profile · 19 shared holders

PERCEPTIVE ADVISORS LLC Kynam Capital Management, LP Candriam S.C.A.

XERS

Xeris Biopharma Holdings, Inc.

AI score

Similar quality profile · 10 shared holders

Parkman Healthcare Partners LLC Rosalind Advisors, Inc.PERCEPTIVE ADVISORS LLC

SEPN

Septerna, Inc.

AI score

Similar quality profile · 10 shared holders

RA CAPITAL MANAGEMENT, L.P.HUSSMAN STRATEGIC ADVISORS, INC.Elmind Capital, LP

SUPN

SUPERNUS PHARMACEUTICALS, INC.

AI score

Similar quality profile · 21 shared holders

RICE HALL JAMES & ASSOCIATES, LLC abrdn plc Susquehanna Portfolio Strategies, LLC

ZLAB

Zai Lab Ltd

AI score

Similar quality profile · 15 shared holders

TCG Crossover Management, LLC RA CAPITAL MANAGEMENT, L.P.Frazier Life Sciences Management, L.P.

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Similar quality profile · 22 shared holders

TCG Crossover Management, LLC Frazier Life Sciences Management, L.P.RA CAPITAL MANAGEMENT, L.P.

SNDX

Syndax Pharmaceuticals Inc

AI score

Similar quality profile · 22 shared holders

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)Kynam Capital Management, LP Candriam S.C.A.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BCRX on your watchlist

Track score changes the day BIOCRYST PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BCRX a good stock to buy?

13F Pro's AI-powered analysis of BIOCRYST PHARMACEUTICALS INC (BCRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCRX are available on the BCRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BCRX is classified as a mid company.

Which hedge funds own BCRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOCRYST PHARMACEUTICALS INC's investment landscape.